Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin’s lymphoma

Tulpule, A.; Rarick, Mark U.; Kolitz, Jonathan E.; Bernstein, Jack; Myers, Adam M.; Buchanan, L.; Espina, Byron M.; Traynor, Ann E.; Letzer, J.; Justice, Glen; McDonald, D.; Roberts, L.; Boswell, William D.; Nathwani, Bharat N.; Levine, Alexandra M.

doi:10.1023/a:1011181016401

Cited by 18 publications

(19 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4,5 Despite its side effects, including cardiac toxicity and bone marrow suppression, 6 the modest lipophicity and net positive charge at physiological pH made DNR an efficient substrate for P-glycoprotein (P-gp). 7,8 P-gp is known to actively pump substrates out of tumor cells through an adenosine triphosphate, resulting in multidrug resistance (MDR) and hampering the…”

Section: Introductionmentioning

confidence: 99%

Daunorubicin and gambogic acid coloaded cysteamine-CdTe quantum dots minimizing the multidrug resistance of lymphoma in vitro and in vivo

Zhou¹,

Wang²,

Chen³

et al. 2016

IJN

View full text Add to dashboard Cite

To minimize the side effects and the multidrug resistance (MDR) arising from daunorubicin (DNR) treatment of malignant lymphoma, a chemotherapy formulation of cysteamine-modified cadmium tellurium (Cys-CdTe) quantum dots coloaded with DNR and gambogic acid (GA) nanoparticles (DNR-GA-Cys-CdTe NPs) was developed. The physical property, drug-loading efficiency and drug release behavior of these DNR-GA-Cys-CdTe NPs were evaluated, and their cytotoxicity was explored by 3-[4,5-dimethylthiazol-2-y1]-2,5-diphenyltetrazolium bromide assay. These DNR-GA-Cys-CdTe NPs possessed a pH-responsive behavior, and displayed a dose-dependent antiproliferative activity on multidrug-resistant lymphoma Raji/DNR cells. The accumulation of DNR inside the cells, revealed by flow cytometry assay, and the down-regulated expression of P-glycoprotein inside the Raji/DNR cells measured by Western blotting assay indicated that these DNR-GA-Cys-CdTe NPs could minimize the MDR of Raji/DNR cells. This multidrug delivery system would be a promising strategy for minimizing MDR against the lymphoma.

show abstract

Section: Introductionmentioning

confidence: 99%

Daunorubicin and gambogic acid coloaded cysteamine-CdTe quantum dots minimizing the multidrug resistance of lymphoma in vitro and in vivo

Zhou¹,

Wang²,

Chen³

et al. 2016

IJN

View full text Add to dashboard Cite

show abstract

“…Overall, approximately a third of patients treated at doses of 100-120 mg/m 2 responded, although patients with indolent histologies were also included [16,19]. COP-X, with DaunoXome in place of doxorubicin in the CHOP regimen, has been used with encouraging response rates in two studies of patients with indolent or with relapsed or refractory NHL [17,18].…”

Section: Discussionmentioning

confidence: 99%

“…Initial clinical studies of DaunoXome focused on Kaposi sarcoma [14] while more recent studies have included patients with NHL [16][17][18][19] and various other hematological malignancies [20,21]. DaunoXome as a single agent demonstrated activity in relapsed or refractory NHL [16,19], which suggested that this agent might be used in place of doxorubicin in the CHOP regimen, with reduced toxicity and equivalent or superior efficacy.…”

Section: Introductionmentioning

confidence: 99%

“…DaunoXome as a single agent demonstrated activity in relapsed or refractory NHL [16,19], which suggested that this agent might be used in place of doxorubicin in the CHOP regimen, with reduced toxicity and equivalent or superior efficacy.…”

Section: Introductionmentioning

confidence: 99%

“…Single agent studies have also shown the same dose range to be well tolerated in patients with previouslytreated NHL [16,19]. Consequently a dose of DaunoXome 100 mg/m 2 was selected for this study, to be given in combination with cyclophosphamide, vincristine and prednisolone (COP-X regimen).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma

Marlton

Grigg

Seymour

et al. 2008

Leukemia & Lymphoma

View full text Add to dashboard Cite

Liposomal daunorubicin (DaunoXome) was substituted for doxorubicin in the CHOP regimen, aiming to reduce toxicity and maintain or improve efficacy in elderly patients. Eligibility criteria included: age >or=60 years; previously untreated aggressive non-Hodgkin Lymphoma (NHL) and performance status (PS) 0-2. Treatment was cyclophosphamide 750 mg/m(2), vincristine 1.4 mg/m(2) (maximum 2 mg), and DaunoXome 100 mg/m(2) i.v. on day 1, prednisolone 100 mg po on days 1-5 and G-CSF 5 microg/kg/day sc, for 6-8 cycles. For the 51 patients, median age was 70 years (range 60-88), 94% had diffuse large B-cell lymphoma (DLBCL) and 55% were high-intermediate or high-risk according to the age-adjusted international prognostic index. A mean of 6 cycles was delivered, with dose reductions of DaunoXome in 8.3% of cycles. The combined CR and CRu rate was 65.2%, survival was 566 days and 5-year survival 35%. Three deaths occurred during treatment and may have been related to COP-X. Only 4 (7.8%) of the remaining patients had >or=10% reduction in LVEF. However, 35% of patients were hospitalised during treatment, mostly for febrile neutropenia. The response rate to COP-X was similar to that expected with CHOP, with low cardiac toxicity. The high rate of infectious complications suggests that the DaunoXome dose used may be too high for this patient group. These results support further investigation of this regimen in patients with aggressive NHL.

show abstract

Current Awareness in Hematological Oncology

2001

Hematological Oncology

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of hematological oncology. Each bibliography is divided into 14 sections: 1 Books, Reviews & Symposia; 2 General; Leukemias: 3 Lymphoblastic; 4 Myeloid & Myelodysplastic Syndromes; 5 Chronic; 6 Others; Lymphomas: 7 Hodgkin's; 8 Non‐Hodgkin's; 9 Plasmacytomas/Multiple Myelomas; 10 Others; 11 Bone Marrow Transplantation; 12 Cytokines; 13 Diagnosis; 14 Cytogenetics. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin’s lymphoma

Abstract: Liposomal daunorubicin at 100 mg/m2 every three weeks has activity in patients with relapsed or refractory NHL, including patients with prior exposure to an anthracycline. Further studies of liposomal daunorubicin in combination with other agents are warranted.

Cited by 18 publications

References 18 publications

Daunorubicin and gambogic acid coloaded cysteamine-CdTe quantum dots minimizing the multidrug resistance of lymphoma in vitro and in vivo

Daunorubicin and gambogic acid coloaded cysteamine-CdTe quantum dots minimizing the multidrug resistance of lymphoma in vitro and in vivo

A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma

Current Awareness in Hematological Oncology

Contact Info

Product

Resources

About